Page last updated: 2024-08-23

selegiline and Depression

selegiline has been researched along with Depression in 37 studies

Research

Studies (37)

TimeframeStudies, this research(%)All Research%
pre-19909 (24.32)18.7374
1990's9 (24.32)18.2507
2000's8 (21.62)29.6817
2010's8 (21.62)24.3611
2020's3 (8.11)2.80

Authors

AuthorsStudies
Dedecengiz, E; Erikci, A; Gokhan-Kelekci, N; Kaynak, FB; Salgin-Goksen, U; Tel, BC; Telli, G; Ucar, G; Yelekci, K1
Han, Y; Huang, S; Liu, K; Liu, S; Xiong, F1
Gómez-Galán, M; Henning, L; Lindskog, M; Srivastava, I; Vazquez-Juarez, E1
Correa, M; Reynolds, S; Salamone, JD; Tripodi, G; Yohn, SE1
Madhav, NVS; Tyagi, Y1
Baqi, Y; Correa, M; Khan, B; Lee, CA; Makriyannis, A; Müller, CE; Nowak, V; Nunes, EJ; Pandit, S; Randall, PA; Salamone, JD; Shah, P; Vemuri, VK; Yohn, SE1
Hallan, SS; Mehra, NK; Mishra, N; Prakash, A; Rashid, M; Singh, D1
Alijanpour, S; Amini-Khoei, H; Amiri, S; Haj-Mirzaian, A; Mehdizadeh, M; Mohammadi-Asl, A; Olson, CO; Rahimi-Balaei, M; Rastegar, M; Razmi, A; Zarrindast, MR1
Keller, D1
Holford, NH; Nutt, JG; Vu, TC2
Robinson, DS1
Herkes, GK; McKay, D; Meagher, LJ; Needham, M1
Morgan, PT1
Pae, CU; Patkar, AA; Zarzar, M1
Knoll, J3
Gershon, S; Mann, J1
Calne, DB; Chuang, LW; Eisler, T; Karoum, F; Klein, DF; Liebowitz, MR; Quitkin, FM; Wyatt, RJ1
Standaert, DG; Stern, MB1
Olanow, CW1
Asnis, J; Patel, SV; Tariot, PN1
Kuhn, W; Müller, T1
Alexander, B; Ritter, JL1
Hauser, RA; Zesiewicz, TA1
Chouinard, S; Fahn, S1
Ballering, LA; Jansen Steur, EN1
Marsh, C; Preskorn, SH; Shad, MU1
Ball, J1
Miyoshi, K1
Mendlewicz, J; Youdim, MB1
Follender, AB; Hughes, PL; Jermain, DM1
Kraus, P; Kuhn, W; Przuntek, H1
Eisenhofer, G; Goldstein, DS; Keiser, HR; Kopin, IJ; Murphy, DL; Stull, R; Sunderland, T1
Agnoli, A; Baronti, F; Denaro, A; Ruggieri, S; Stocchi, F1
Baas, H; Fischer, PA1

Reviews

7 review(s) available for selegiline and Depression

ArticleYear
Transdermal selegiline.
    Drugs of today (Barcelona, Spain : 1998), 2007, Volume: 43, Issue:6

    Topics: Administration, Cutaneous; Antidepressive Agents; Depression; Drug Interactions; Food-Drug Interactions; Humans; Monoamine Oxidase Inhibitors; Selegiline

2007
Update on the management of Parkinson's disease.
    The Medical clinics of North America, 1993, Volume: 77, Issue:1

    Topics: Depression; Diagnosis, Differential; Dopamine Agents; Hallucinations; Humans; Levodopa; Parkinson Disease; Selegiline

1993
The clinical potential of Deprenyl in neurologic and psychiatric disorders.
    Journal of neural transmission. Supplementum, 1996, Volume: 48

    Topics: Adult; Aged; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Antipsychotic Agents; Child; Clinical Trials as Topic; Cross-Over Studies; Depression; Double-Blind Method; Humans; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Narcolepsy; Nervous System Diseases; Neuroprotective Agents; Nootropic Agents; Parkinson Disease, Secondary; Schizophrenia; Selegiline; Supranuclear Palsy, Progressive; Tourette Syndrome; Treatment Outcome

1996
Retrospective study of selegiline-antidepressant drug interactions and a review of the literature.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1997, Volume: 9, Issue:1

    Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Bupropion; Comorbidity; Depression; Drug Interactions; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Selegiline

1997
[Parkinson's disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:8

    Topics: Antiparkinson Agents; Depression; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline

2001
Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.
    CNS drug reviews, 2001,Fall, Volume: 7, Issue:3

    Topics: Aging; Alzheimer Disease; Animals; Benzofurans; Brain; Catecholamines; Depression; Humans; Neuroprotective Agents; Parkinson Disease; Propylamines; Selegiline; Serotonin

2001
The facilitation of dopaminergic activity in the aged brain by (-)deprenyl. A proposal for a strategy to improve the quality of life in senescence.
    Mechanisms of ageing and development, 1985, May-13, Volume: 30, Issue:2

    Topics: Aged; Aging; Animals; Brain; Depression; Dopamine; Geriatrics; Humans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Quality of Life; Rats; Selegiline; Sexual Behavior

1985

Trials

4 trial(s) available for selegiline and Depression

ArticleYear
Sertraline for the treatment of depression in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1997, Volume: 12, Issue:5

    Topics: 1-Naphthylamine; Aged; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Depression; Drug Interactions; Drug Therapy, Combination; Humans; Parkinson Disease; Pilot Projects; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline; Severity of Illness Index; Treatment Outcome

1997
Experience with tranylcypromine in early Parkinson's disease.
    Journal of neural transmission. Supplementum, 1998, Volume: 52

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Depression; Erectile Dysfunction; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders; Time Factors; Tranylcypromine; Tyramine

1998
Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease.
    Advances in neurology, 1999, Volume: 80

    Topics: Adult; Aged; Benzamides; Cognition; Depression; Drug Combinations; Female; Humans; Male; Medical Records; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Movement; Parkinson Disease; Selegiline

1999
Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism.
    Journal of neural transmission. Supplementum, 1987, Volume: 25

    Topics: Aged; Clinical Trials as Topic; Depression; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Thioxanthenes

1987

Other Studies

26 other study(ies) available for selegiline and Depression

ArticleYear
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
    Journal of medicinal chemistry, 2021, 02-25, Volume: 64, Issue:4

    Topics: Animals; Antidepressive Agents; Depression; Hep G2 Cells; Humans; Hydrazones; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Pyrazoles; Structure-Activity Relationship

2021
The novel design of an intelligent anti-depression transdermal drug delivery system.
    Biomaterials, 2023, Volume: 303

    Topics: Administration, Cutaneous; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Drug Delivery Systems; Hippocampus; Humans; Rats; Selegiline

2023
Blocking Astrocytic GABA Restores Synaptic Plasticity in Prefrontal Cortex of Rat Model of Depression.
    Cells, 2020, 07-16, Volume: 9, Issue:7

    Topics: Animals; Astrocytes; Atrophy; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; Long-Term Potentiation; Male; Neuronal Plasticity; Prefrontal Cortex; Rats, Sprague-Dawley; Receptors, GABA; Selegiline

2020
The monoamine-oxidase B inhibitor deprenyl increases selection of high-effort activity in rats tested on a progressive ratio/chow feeding choice procedure: Implications for treating motivational dysfunctions.
    Behavioural brain research, 2018, 04-16, Volume: 342

    Topics: Animal Feed; Animals; Antidepressive Agents; Behavior, Animal; Choice Behavior; Conditioning, Operant; Depression; Dopamine; Feeding Behavior; Male; Models, Animal; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motivation; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Selegiline

2018
Design of selegiline-loaded bio-nanosuspension for the management of depression using novel bio-retardant from
    Drug development and industrial pharmacy, 2019, Volume: 45, Issue:8

    Topics: Chemistry, Pharmaceutical; Depression; Drug Delivery Systems; Drug Liberation; Manilkara; Nanoparticles; Particle Size; Plant Extracts; Polymers; Selegiline; Solubility; Solvents; Suspensions; X-Ray Diffraction

2019
The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Animals; Antidepressive Agents; Benzazepines; Benzophenones; Bupropion; Cannabinoid Receptor Antagonists; Choice Behavior; Depression; Dopamine Antagonists; Drug Evaluation, Preclinical; Feeding Behavior; Male; Nitrophenols; Pyrazoles; Rats, Sprague-Dawley; Salicylamides; Selegiline; Tetrabenazine; Tolcapone; Vesicular Monoamine Transport Proteins; Xanthines

2014
Pharmacological evaluation of nasal delivery of selegiline hydrochloride-loaded thiolated chitosan nanoparticles for the treatment of depression.
    Artificial cells, nanomedicine, and biotechnology, 2016, Volume: 44, Issue:3

    Topics: Administration, Intranasal; Animals; Antidepressive Agents; Chitosan; Depression; Disease Models, Animal; Drug Evaluation, Preclinical; Male; Nanoparticles; Rats; Rats, Wistar; Selegiline

2016
Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse.
    Physiology & behavior, 2016, 09-01, Volume: 163

    Topics: Analysis of Variance; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Exploratory Behavior; Female; Food Preferences; Grooming; Male; Maternal Deprivation; Mice; Motivation; Receptors, Dopamine D1; Receptors, Dopamine D2; Selegiline; Swimming

2016
MAO inhibitors.
    Cleveland Clinic journal of medicine, 2011, Volume: 78, Issue:2

    Topics: Depression; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline

2011
Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.
    British journal of clinical pharmacology, 2012, Volume: 74, Issue:2

    Topics: Antiparkinson Agents; Cognition Disorders; Depression; Disability Evaluation; Disease Progression; Drug Substitution; Drug Therapy, Combination; Gait Disorders, Neurologic; Humans; Hypokinesia; Linear Models; Motor Activity; Nonlinear Dynamics; Parkinson Disease; Patient Dropouts; Postural Balance; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline; Sensation Disorders; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Tocopherols; Treatment Outcome; Tremor

2012
Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.
    British journal of clinical pharmacology, 2012, Volume: 74, Issue:2

    Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Chi-Square Distribution; Cognition; Cognition Disorders; Depression; Disability Evaluation; Disease Progression; Humans; Kaplan-Meier Estimate; Middle Aged; Parkinson Disease; Patient Dropouts; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Selegiline; Severity of Illness Index; Time Factors; Tocopherols; Treatment Outcome

2012
Monoamine oxidase inhibitors: a new generation.
    Psychopharmacology bulletin, 2002,Summer, Volume: 36, Issue:3

    Topics: Administration, Cutaneous; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Monoamine Oxidase Inhibitors; Selegiline

2002
Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2006, Volume: 13, Issue:8

    Topics: Acetaminophen; Acyclovir; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiparkinson Agents; Antiviral Agents; Anxiety; Carbidopa; Ceftriaxone; Cervical Vertebrae; Depression; Dexamethasone; Diazepam; Doxepin; Electroconvulsive Therapy; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Oxycodone; Pain; Parkinson Disease; Selegiline; Spinal Injuries

2006
Treatment-resistant depression: response to low-dose transdermal but not oral selegiline.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:3

    Topics: Administration, Cutaneous; Aged; Depression; Drug Administration Routes; Drug Resistance; Humans; Male; Monoamine Oxidase Inhibitors; Selegiline

2007
Deprenyl (selegiline): the history of its development and pharmacological action.
    Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95

    Topics: Aging; Animals; Brain; Depression; Dopamine; Drug Evaluation; History, 20th Century; Humans; Male; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Phenethylamines; Rats; Rats, Inbred Strains; Selegiline; Sexual Behavior

1983
L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression.
    Life sciences, 1980, Mar-17, Volume: 26, Issue:11

    Topics: Adult; Blood Platelets; Depression; Drug Evaluation; Female; Humans; Middle Aged; Monoamine Oxidase; Phenethylamines; Selegiline

1980
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
    Neurology, 1982, Volume: 32, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amphetamines; Biogenic Amines; Carbidopa; Depression; Drug Combinations; Female; Humans; Levodopa; Male; Methamphetamine; Middle Aged; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Tyramine

1982
A 61-year-old man with Parkinson's disease.
    JAMA, 1996, Mar-06, Volume: 275, Issue:9

    Topics: 1-Naphthylamine; Antiparkinson Agents; Carbidopa; Depression; Dopamine Agents; Drug Interactions; Drug Therapy, Combination; Family Practice; Humans; Levodopa; Male; Middle Aged; Neurology; Neuroprotective Agents; Parkinson Disease; Selegiline; Sertraline; Vitamin E

1996
L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1996, Volume: 8, Issue:1

    Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Attention; Carbamazepine; Depression; Drug Interactions; Drug Therapy, Combination; Expressed Emotion; Female; Fluoxetine; Humans; Huntington Disease; Impulsive Behavior; Monoamine Oxidase Inhibitors; Movement; Selegiline; Violence

1996
The economic consequences of a drug-drug interaction.
    Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:1

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Haloperidol; Health Care Costs; Humans; Olanzapine; Parkinson Disease; Pirenzepine; Selegiline; Trihexyphenidyl

2001
Current advances in Parkinson's disease.
    Trends in neurosciences, 2001, Volume: 24, Issue:7

    Topics: Antidepressive Agents; Antiparkinson Agents; Benzothiazoles; Brain Stem; Catechols; Depression; Dopamine Agonists; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles

2001
Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor.
    Journal of neural transmission, 1978, Volume: 43, Issue:3-4

    Topics: Adult; Antidepressive Agents; Depression; Drug Synergism; Drug Therapy, Combination; Female; Humans; Informed Consent; Male; Middle Aged; Phenethylamines; Selegiline; Serotonin

1978
Potential fluoxetine-selegiline interaction.
    The Annals of pharmacotherapy, 1992, Volume: 26, Issue:10

    Topics: Aged; Ataxia; Depression; Drug Interactions; Female; Fluoxetine; Humans; Parkinson Disease; Selegiline

1992
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.
    Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126

    Topics: Benserazide; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Glycols; Homovanillic Acid; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Motor Activity; Parkinson Disease; Phenethylamines; Selegiline

1989
Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase.
    Clinical chemistry, 1986, Volume: 32, Issue:11

    Topics: Alzheimer Disease; Animals; Catecholamines; Chromatography, Liquid; Depression; Dihydroxyphenylalanine; Dogs; Glycols; Humans; Methoxyhydroxyphenylglycol; Monoamine Oxidase Inhibitors; Posture; Quality Control; Selegiline; Tranylcypromine

1986
The role of MAO-b inhibitors in the treatment of Parkinson's disease.
    Journal of neural transmission. Supplementum, 1986, Volume: 22

    Topics: Adult; Aged; Depression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline

1986